Phase I study of docetaxel plus ifosfamide in patients with advanced cancer

British Journal of Cancer

Volumn 87, Issue 8, 2002, Pages 846-849

  Marx, G ^a   Lewis, C ^a   Hall, K ^b   Levi, J ^c   Ackland, S ^b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b NEWCASTLE MATER HOSPITAL   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Docetaxel; G CSF; Ifosfamide; Malignancy; Toxicity

Indexed keywords

ACROLEIN; ANTIEMETIC AGENT; CORTICOSTEROID; DEXAMETHASONE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HEMORRHAGIC CYSTITIS; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; PERIPHERAL EDEMA; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL DISEASES; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HUMANS; IFOSFAMIDE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; TAXOIDS;

EID: 0037037329     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600542     Document Type: Article

References (22)

1. Aihara T, Kim Y, Takatsuka Y (2002) 'Phase II study of weekly docetaxel in patients with metastatic breast cancer.' Ann Oncol 13: 286-292
2. Bizzari J, Bail NL (1994) 'Taxotere. Docetaxel:RP56976. Integrated Safety Summary. Updated Analysis 25 October 1994.' Data on file Rhone-Poulenc Rorer
3. Cerny T, Castiglione M, Brunner K, Kupfer A, Martinelli G, Lind M (1990) 'Ifosfamide by continuous infusion to prevent encephalopathy.' Lancet 335: 175
4. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M (1993) 'Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.' Cancer Res 53: 1037-1042
5. Kavanagh JJ, Kudelka AP, de Leon CG, Tresukosol D, Hord M, Finnegan MB, Kim EE, Varma D, Forman A, Cohen P, Edwards CL, Freedman RS, Verschraegen CF (1996) 'Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum.' Clin Cancer Res 2: 837-842
6. Kaye SB (2001) 'The integration of docetaxel into first-line chemotherapy for ovarian cancer.' Int J Gynecol Cancer 11(Suppl 1): 31-33
7. Kaye SB, Mead GM, Fossa S, Cullen M, de Wit R, Bodrogi I, van Groeningen C, Sylvester R, Collette L, Stenning S, De Prijck L, Lallemand E, DeMuller P (1998) 'Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: A Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.' J Clin Oncol 16: 692-701
8. Lind MJ, Roberts HL, Thatcher N, Idle JR (1990) 'The effect of route of administration and fractionation of dose on the metabolism of ifosfamide.' Cancer Chemother Pharmacol 26: 105-111
9. Meanwell CA, Blake AE, Kelly KA, Honigsberger L, Blackledge G (1986) 'Prediction of ifosfamide/mesna associated encephalopathy.' Eur J Cancer Clin Oncol 22: 815-819
10. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) 'Reporting results of cancer treatment.' Cancer 47: 207-214
11. Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O'Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yahalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD (1999) 'Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.' J Clin Oncol 17: 3776-3785
12. Nabholtz JM, Mackey JR, Smylie M, Paterson A, Noel DR, Al-Tweigeri T, Tonkin K, North S, Azli N, Riva A (2001) 'Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.' J Clin Oncol 19: 314-321
13. Pazdur R, Newman RA, Newman BM, Fuentes A, Benvenuto J, Bready B et al (1992) 'Phase I trial of Taxotere: five-day schedule.' J Natl Cancer Inst 84: 1781-1788
14. Pinedo HM, Verweij J (1986) 'The treatment of soft tissue sarcomas with focus on chemotherapy: a review.' Radiother Oncol 5: 193-205
15. Pronk LC, Schrijvers D, Schellens JH, de Bruijn EA, Planting AS, Locci-Tonelli D, Groult V, Verweij J, van Oosterom A (1998) 'Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.' Br J Cancer 77: 153-158
16. Ravdin PM, Burris III HA, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE (1995) 'Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.' J Clin Oncol 13: 2879-2885
17. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M, Goldhirsch A (2000) 'Docetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).' Ann Oncol 11: 301-306
18. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) 'Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.' J Clin Oncol 18: 2095-2103
19. Shirinian M, Lee JS, Dhingra HH, Greenberg J, Hong WK (1992) 'Phase II study of cisplatin, ifosfamide, and etoposide combination for advanced non-small cell lung cancer: final report.' Semin Oncol 19(6 Suppl 12): 58-63
20. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN (2002) 'Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel.' J Clin Oncol 20: 1456-1466
21. Tomiak E, Piccart MJ, Kerger J, Lips S, Awada A, de Valeriola D et al (1994) 'Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.' J Clin Oncol 12: 1458-1467
22. Watkin SW, Husband DJ, Green JA, Warenius HM (1989) 'Ifosfamide encephalopathy: A reappraisal.' Eur J Cancer Clin Oncol 25: 1303-1310